Need for a Standardized Translational Drug Development Platform: Lessons Learned from the Repurposing of Drugs for COVID-19

In the absence of drugs to treat or prevent COVID-19, drug repurposing can be a valuable strategy. Despite a substantial number of clinical trials, drug repurposing did not deliver on its promise. While success was observed with some repurposed drugs (e.g., remdesivir, dexamethasone, tocilizumab, ba...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Frauke Assmus, Jean-Sélim Driouich, Rana Abdelnabi, Laura Vangeel, Franck Touret, Ayorinde Adehin, Palang Chotsiri, Maxime Cochin, Caroline S. Foo, Dirk Jochmans, Seungtaek Kim, Léa Luciani, Grégory Moureau, Soonju Park, Paul-Rémi Pétit, David Shum, Thanaporn Wattanakul, Birgit Weynand, Laurent Fraisse, Jean-Robert Ioset, Charles E. Mowbray, Andrew Owen, Richard M. Hoglund, Joel Tarning, Xavier de Lamballerie, Antoine Nougairède, Johan Neyts, Peter Sjö, Fanny Escudié, Ivan Scandale, Eric Chatelain
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	MDPI AG 2022-08-01
Schriftenreihe:	Microorganisms
Schlagworte:	COVID-19 drug repurposing translational medicine pandemics clinical trials
Online-Zugang:	https://www.mdpi.com/2076-2607/10/8/1639
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!